Biotech entity

Corcept Therapeutics Incorporated

Company CORT

All 1 tracked stories fall under one category: pharma. Korlym is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Corcept Therapeutics Incorporated, all published on February 24, 2026.

Last mentioned: Feb 24, 2026

Entity pulse

Recent coverage · Corcept Therapeutics Incorporated

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Corcept Therapeutics Incorporated

All 1 tracked stories fall under one category: pharma. Korlym is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Corcept Therapeutics Incorporated, all published on February 24, 2026. Each carries 10 original sources on average.

Stories tracked
1
Sources per story
10

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Corcept Therapeutics Incorporated. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Lawsuit Announced

    Rosen Law Firm announces the filing of the securities fraud class action.

  2. Appellate Loss

    Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.

  3. Class Period Ends

    Conclusion of the period following corrective disclosures or market events.

  4. Class Period Begins

    Start of the period during which alleged misleading statements were made.

Stories mentioning Corcept Therapeutics Incorporated 1

Pharma Neutral

Corcept Therapeutics Faces Securities Fraud Lawsuit Amid Korlym Patent Battle

Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.

10 sources

Corcept Therapeutics Incorporated is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.